Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. - Wikidata - awgldk - TriplyDB

Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency.

Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency.

http://www.wikidata.org/entity/Q45413952

about

Advances of gene therapy for primary immunodeficiencies Recent advances in treatment of severe primary immunodeficiencies Use of V(D)J recombination excision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency.Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases.Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products.Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency.Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases.Gene therapy for inherited immunodeficiency.Hematopoietic stem cell transplantation for primary immunodeficiencies.Clinical applications of gene therapy for primary immunodeficiencies.What has happened in the last 50 years in immunology.History and current status of newborn screening for severe combined immunodeficiency.B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients.Intrathymic progenitor cell transplantation across histocompatibility barriers results in the persistence of early thymic progenitors and T-cell differentiation.Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State Long-term outcome of non-ablative booster BMT in patients with SCID Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.Gene therapy for primary immune deficiencies: a Canadian perspective.Haematopoietic stem cell transplantation for SCID patients: where do we stand?Concise review: hematopoietic stem cell transplantation: targeting the thymus.Unresolved issues in hematopoietic stem cell transplantation for severe combined immunodeficiency: need for safer conditioning and reduced late effects.Lentiviral vectors for the treatment of primary immunodeficiencies.Moonlighting adenosine deaminase: a target protein for drug development.Inborn errors of metabolism underlying primary immunodeficiencies.Primary immunodeficiencies: a decade of shifting paradigms, the current status and the emergence of cutting-edge therapies and diagnostics.Severe combined immunodeficiency: recent developments and guidance on clinical management.Gene therapy for primary immunodeficiencies.Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Conso Erythrocyte-mediated delivery of recombinant enzymes.Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening.Periodontal and other oral manifestations of immunodeficiency diseases.How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).Evolving Gene Therapy in Primary Immunodeficiency.Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network.Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.Infusion of Sibling Marrow in a Patient with Purine Nucleoside Phosphorylase Deficiency Leads to Split Mixed Donor Chimerism and Normal Immunity.Diagnosis, Treatment and Long-Term Follow Up of Patients with ADA Deficiency: a Single-Center Experience.Longitudinal Evaluation of Immune Reconstitution and B-cell Function After Hematopoietic Cell Transplantation for Primary Immunodeficiency.

P2860

Q26742031-3F31DA0C-7F1A-44D2-B23D-A73B1FCD0A95 Q26766170-8A86A89D-1DD9-4569-9A98-BC3CC2DC931E Q26827084-64AF3C00-95C9-42CC-A151-E12E5BC84114 Q33403252-A03073CE-E156-4644-85C1-3A76438E4E0E Q33552027-6CF14F47-2FFB-483E-B9C0-76F07B3DAEC7 Q33749021-1A13099E-7C1E-49DC-8FE9-73867CA3074A Q34294647-DAAEC8C0-6729-4016-AEAC-02C35B25ABE2 Q34401676-46ED94B2-748D-4637-9B1F-3447B8208333 Q34419791-89F1C57C-E0B6-4534-B4EF-C4A5F1455D6E Q34630754-AF1C4A03-0412-4763-91C4-1206AFC7BC39 Q35539617-297CC606-41FD-4E09-9528-BAD9586D84A6 Q35560218-FDAC423D-010B-42C2-A4C6-4F9C44A0EE92 Q35613205-505F04E7-1959-45AE-90F9-0AFFFEA773F1 Q35810860-2614E978-7D87-4CB2-8C03-15292D62D43E Q36682879-7EB851C0-3511-4EC9-B767-623D6BA54AC2 Q36839938-A4998766-6C62-4891-B885-E66723CF90AC Q37079714-3A7BF086-6B26-41D2-A9FC-45317E621D3B Q37664729-173160DC-20E9-4626-B976-C70EB37CA5D5 Q37668317-64C50F74-3421-4543-BCEF-939E7085ADD3 Q38061148-D7908B1F-58AC-465D-9D68-AEBFE959144C Q38095902-A1FCB16F-31C9-4811-B262-DBE02D119EAB Q38102101-B9E586DE-6C19-48BB-A570-C757F6D8CB11 Q38195200-2F557D40-F33A-4FE9-87E8-A0C3F28D09CD Q38220597-9057378A-C326-4F97-9323-11AD7C5DCC6D Q38235840-E8120ED1-D0A9-41F0-9DCB-90E769A718B7 Q38289442-6BCC4EBE-C1DC-434E-8DDF-39CDCA733F45 Q38309572-094A8BAC-9517-4ECA-9C24-399A98D32F07 Q38364511-574FDA42-C814-45EA-AF01-AE05E928DD2A Q38772827-DE99D341-940F-4BA2-8504-61CD7311EABB Q38793040-C83E0370-0BE9-4B71-AA78-D667E356EE0F Q38874124-4461C745-FA61-42BD-8016-97AB2BC27CC2 Q38922397-981F1389-507A-4323-9CB9-06A9599011EB Q38954801-4A0B0E78-FE8E-49D0-AECA-25C698791A09 Q39134501-05769653-21D0-4A56-B9CF-E894F1911253 Q39214064-B8088781-29A2-45D2-8808-E3A72AD55F66 Q40070985-238C8229-7BCA-4C00-84D0-575420DB1CE9 Q40117791-42174BE2-5E1A-43E9-AF87-298EF53CD804 Q40135959-26FF7D9B-5EBE-49B2-9E54-739DBCC2FB27 Q40533048-C034BBB7-FB74-4572-A366-D5FBE825891D Q41070585-FAAD5D1C-0581-4105-9688-3DC9AE815067

P2860

Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency.

http://www.wikidata.org/entity/Q45413952

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Outcome of hematopoietic stem ...... ere combined immunodeficiency.

@en

Outcome of hematopoietic stem ...... ere combined immunodeficiency.

@nl

type

label

Outcome of hematopoietic stem ...... ere combined immunodeficiency.

@en

Outcome of hematopoietic stem ...... ere combined immunodeficiency.

@nl

prefLabel

Outcome of hematopoietic stem ...... ere combined immunodeficiency.

@en

Outcome of hematopoietic stem ...... ere combined immunodeficiency.

@nl

P1433

Q45413952-8C7FC88D-BC34-4E19-B4EF-B0E9A1B1883D

P1476

Q45413952-D120217B-A333-4746-AA88-10D7F255459A

P2093

Q45413952-10C1D297-9605-4F56-90D1-FA9EE469C9BA

Q45413952-114C76C5-A214-4FBF-ABFA-A099F5046F11

Q45413952-1F84A714-0613-4824-BF8D-A02FA385C9B7

Q45413952-245B9F45-BF9C-41B6-A332-265AB16D97B6

Q45413952-25DD8C2E-F808-478D-A386-3FE347750121

Q45413952-28AFCCCE-F31F-4665-B0B2-F12D772ABF3B

Q45413952-3472ECD5-9130-4713-B946-07854131DC7D

Q45413952-38A74489-1C23-41C7-BAE7-648F9202987A

Q45413952-54C27F20-1884-4368-8567-2D63615CDADE

Q45413952-55018377-5AF8-49C8-AB6A-FA30D8564822

P304

Q45413952-C0EA0C16-BA0D-42B7-B907-CDDC2580C3AA

P31

Q45413952-5AF3E09E-7761-4FA6-8C15-500CD692014D

P356

Q45413952-639BE7C6-FA7B-4882-A0B9-BACC9A0BAFD3

P407

Q45413952-8327FAC9-9C49-47A1-9AC2-27B51EAEFD5B

P433

Q45413952-C05E9A4D-D49B-4B92-9C4C-65D8C7DBD4D0

P478

Q45413952-D006AA97-5C26-41E1-831C-184300617690

P50

Q45413952-101B1B57-3677-4144-89EC-72E524D92BFE

Q45413952-12DB0AA1-E889-48E7-9A80-9BC2A37FA147

Q45413952-3A1EA0BE-4E6C-4789-937F-1EC149DE858E

Q45413952-41C4348F-360B-4422-BD12-8BFE19ECC260

Q45413952-46202089-7061-434E-9EB5-02AD0DF0B930

Q45413952-4E26C0AA-6532-4E41-B95E-7DD1253D60BC

Q45413952-54F436E1-DE5F-4EDB-A084-269ED9754197

Q45413952-A4E99FC8-043C-49CB-B60C-C6858B2FB61F

Q45413952-C5014056-6CEB-443C-BF3C-1F01DE4FBF9B

Q45413952-FDFEF85E-251F-4EDF-8150-A765191747FA

P577

Q45413952-D2FAE66B-CEEA-414B-AFCA-7B3EC466B316

P5875

Q45413952-8AED09E0-12CD-4207-B3C4-E2B66BD1A802

P698

Q45413952-51DE2342-B3B6-434E-8067-8020652C902A

P356

BLOOD-2011-12-396879

P1433

P1476

Outcome of hematopoietic stem ...... vere combined immunodeficiency

@en

P2093

Abdulaziz Al Ghonaium

http://www.w3.org/2001/XMLSchema#string

Alain Fischer

http://www.w3.org/2001/XMLSchema#string

Alex Brightwell

http://www.w3.org/2001/XMLSchema#string

Alexandra Filipovich

http://www.w3.org/2001/XMLSchema#string

Amel Hassan

http://www.w3.org/2001/XMLSchema#string

Andrew Gennery

http://www.w3.org/2001/XMLSchema#string

Arnalda Lanfranchi

http://www.w3.org/2001/XMLSchema#string

Chaim M Roifman

http://www.w3.org/2001/XMLSchema#string

Daifulah Al Zahrani

http://www.w3.org/2001/XMLSchema#string

E Graham Davies

http://www.w3.org/2001/XMLSchema#string

P304

3615-24; quiz 3626

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-12-396879

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

Marina Cavazzana-Calvo

Jaap J. Boelens

Alessandro Aiuti

Andrea Finocchi

Caterina Cancrini

Carsten Speckmann

Victoria Bordon

P577

2012-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229082308

http://www.w3.org/2001/XMLSchema#string

P698

22791287

http://www.w3.org/2001/XMLSchema#string